6. The Safety of Long-Acting Beta-Agonists and the Development of Combination Therapies for Asthma and COPD

  1. Jan Lötvall
  1. Victor E. Ortega and
  2. Eugene R. Bleecker

Published Online: 29 FEB 2012

DOI: 10.1002/9781119998624.ch6

Advances in Combination Therapy for Asthma and COPD

Advances in Combination Therapy for Asthma and COPD

How to Cite

Ortega, V. E. and Bleecker, E. R. (2012) The Safety of Long-Acting Beta-Agonists and the Development of Combination Therapies for Asthma and COPD, in Advances in Combination Therapy for Asthma and COPD (ed J. Lötvall), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119998624.ch6

Editor Information

  1. Krefting Research Centre, University of Gothenburg, Göteborg, Sweden

Author Information

  1. Center for Human Genomics and Personalized Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA

Publication History

  1. Published Online: 29 FEB 2012
  2. Published Print: 3 FEB 2012

ISBN Information

Print ISBN: 9780470727027

Online ISBN: 9781119998624

SEARCH

Keywords:

  • long-acting beta-agonists, and safety;
  • combination therapies, for asthma, COPD;
  • asthma-related mortality;
  • beta-agonist exposure;
  • long-acting beta-agonists;
  • asthma-related mortality;
  • LABA therapy in asthma, and safety;
  • LABA therapy efficacy;
  • beta-agonist, adverse in COPD;
  • LABAs pharmacogenetics

Summary

This chapter contains sections titled:

  • Introduction

  • Asthma-related mortality and beta-agonist exposure

  • Long-acting beta-agonists and increased asthma-related mortality

  • Safety and efficacy of LABA therapy in asthma: retrospective analyses

  • Efficacy of LABA therapy as a component of combination therapy with ICS for the management of asthma

  • Scientific basis of the beneficial and adverse effects of beta-agonist therapy: in vitro data and the beta-agonist paradox

  • Conclusions regarding the safety of LABA therapy as a component of combination therapy with ICS for the management of asthma

  • Beta-agonist therapy and adverse events in COPD

  • Safety and efficacy of LABA therapy in the management of COPD: the clinical evidence

  • Role of LABA therapy as a component of combination therapy with ICS for the management of COPD

  • Conclusions regarding the safety of LABA therapy as a component of combination therapy for the management of COPD

  • Pharmacogenetics of LABAs and combination therapy

  • Safety and efficacy of LABA therapy and the development of combination therapies for the management of asthma and COPD

  • Summary and future directions

  • Acknowledgement

  • References